231 related articles for article (PubMed ID: 36692689)
61. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
[TBL] [Abstract][Full Text] [Related]
62. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
[TBL] [Abstract][Full Text] [Related]
63. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
[TBL] [Abstract][Full Text] [Related]
64. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
[TBL] [Abstract][Full Text] [Related]
65. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
66. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
67. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
[TBL] [Abstract][Full Text] [Related]
68. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
Front Oncol; 2022; 12():938392. PubMed ID: 36276097
[TBL] [Abstract][Full Text] [Related]
69. A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma.
Liu J; Wang C; Guo W; Zeng P; Liu Y; Lang N; Yuan H
Radiol Med; 2021 Sep; 126(9):1226-1235. PubMed ID: 34159496
[TBL] [Abstract][Full Text] [Related]
70. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
71. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau H; Attal M; Moreau P; Charbonnel C; Garban F; Hulin C; Leyvraz S; Michallet M; Yakoub-Agha I; Garderet L; Marit G; Michaux L; Voillat L; Renaud M; Grosbois B; Guillerm G; Benboubker L; Monconduit M; Thieblemont C; Casassus P; Caillot D; Stoppa AM; Sotto JJ; Wetterwald M; Dumontet C; Fuzibet JG; Azais I; Dorvaux V; Zandecki M; Bataille R; Minvielle S; Harousseau JL; Facon T; Mathiot C
Blood; 2007 Apr; 109(8):3489-95. PubMed ID: 17209057
[TBL] [Abstract][Full Text] [Related]
72. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
73. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
[TBL] [Abstract][Full Text] [Related]
74. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
[TBL] [Abstract][Full Text] [Related]
75. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities.
Lim JH; Seo EJ; Park CJ; Jang S; Chi HS; Suh C; Kim H; Kim SR
Eur J Haematol; 2014 Apr; 92(4):313-20. PubMed ID: 24372944
[TBL] [Abstract][Full Text] [Related]
76. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
77. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
78. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
[TBL] [Abstract][Full Text] [Related]
79. Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma.
Kim M; Ju YS; Lee EJ; Kang HJ; Kim HS; Cho HC; Kim HJ; Kim JA; Lee DS; Lee YK
Ann Lab Med; 2016 Nov; 36(6):573-82. PubMed ID: 27578511
[TBL] [Abstract][Full Text] [Related]
80. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
